170 related articles for article (PubMed ID: 2386978)
1. Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.
Gregorian SK; Battisto JR
Cancer Immunol Immunother; 1990; 31(6):325-34. PubMed ID: 2386978
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression in murine renal cell carcinoma. II. Identification of responsible lymphoid cell phenotypes and examination of elimination of suppression.
Gregorian SK; Battisto JR
Cancer Immunol Immunother; 1990; 31(6):335-41. PubMed ID: 1974826
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
4. Improved lymphocyte cytotoxicity against murine renal cell carcinoma.
Salup RR; Sicker DC; Ballou BT; Flack CE; Wolmark N; Hakala TR
J Urol; 1992 Feb; 147(2):491-5. PubMed ID: 1732630
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
6. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
8. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma.
Lau BH; Ruckle HC; Botolazzo T; Lui PD
Cancer Biother; 1994; 9(2):153-61. PubMed ID: 7812364
[TBL] [Abstract][Full Text] [Related]
9. [Effect of biological response modifiers on a spontaneous murine renal cell carcinoma regression of metastases caused by the streptococcal preparation OK-432].
Tanji S
Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):716-25. PubMed ID: 1875566
[TBL] [Abstract][Full Text] [Related]
10. Tumor site-dependent differential modulation of systemic immunity in RENCA bearing mice.
Yoon HL; Choi KM; Jung YS; Park CH; Yoon SS
In Vivo; 1999; 13(5):407-13. PubMed ID: 10654194
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
12. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
[TBL] [Abstract][Full Text] [Related]
13. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma and natural killer cells: studies in a novel rat model in vitro and in vivo.
Winter BK; Wu S; Nelson AC; Pollack SB
Cancer Res; 1992 Nov; 52(22):6279-86. PubMed ID: 1423274
[TBL] [Abstract][Full Text] [Related]
15. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
[TBL] [Abstract][Full Text] [Related]
16. Generation of activated killer cells in tumor-bearing hosts.
Ting CC; Hargrove ME; Stephany D
Int J Cancer; 1987 Feb; 39(2):232-9. PubMed ID: 3100459
[TBL] [Abstract][Full Text] [Related]
17. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
18. Antiviral effect of lymphokine-activated killer cells: characterization of effector cells mediating prophylaxis.
Bukowski JF; Yang H; Welsh RM
J Virol; 1988 Oct; 62(10):3642-8. PubMed ID: 2458485
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
20. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
